Compare · JNJ vs PG
JNJ vs PG
Side-by-side comparison of Johnson & Johnson (JNJ) and Procter & Gamble Company (PG): market cap, price performance, sector, and recent activity on the wire.
Summary
- JNJ operates in Health Care, while PG operates in Consumer Discretionary - the two are in different parts of the market.
- JNJ is the larger of the two at $680.19B, about 1.7x PG ($401.02B).
- PG has been more active in the news (29 items in the past 4 weeks vs 14 for JNJ).
- Both have 25 recent analyst ratings on file.
- Company
- Johnson & Johnson
- Procter & Gamble Company
- Price
- -
- -
- Market cap
- $680.19B
- $401.02B
- 1M return
- +9.76%
- -
- 1Y return
- +39.68%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Package Goods/Cosmetics
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 14
- 29
- Recent ratings
- 25
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Procter & Gamble Company
The Procter & Gamble Company provides branded consumer packaged goods to consumers in North and Latin America, Europe, the Asia Pacific, Greater China, India, the Middle East, and Africa. It operates in five segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers conditioners, shampoos, styling aids, and treatments; and antiperspirants and deodorants, personal cleansing, and skin care products under the Head & Shoulders, Herbal Essences, Pantene, Rejoice, Olay, Old Spice, Safeguard, Secret, and SK-II brands. The Procter & Gamble Company was founded in 1837 and is headquartered in Cincinnati, Ohio.
Latest JNJ
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
- EVP, Chief Legal Officer Forminard Elizabeth exercised 13,072 shares at a strike of $151.41 and sold $3,717,546 worth of shares (13,072 units at $284.39) (SEC Form 4)
- FDA Approval for LAZCLUZE issued to JANSSEN BIOTECH
- Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Latest PG
- From Lumberjacks to Jacked Snowmen, Old Spice Delivers 24/7 Holiday Freshness Across Six Limited Edition Holiday Scents
- CEO-Baby and Feminine Care Abd El Hak Hesham sold $379,058 worth of shares (2,250 units at $168.47), decreasing direct ownership by 20% to 8,968 units (SEC Form 4)
- Pampers Partners with Witney Carson to Launch Baby Registry Sweepstakes
- Herbal Essences Brings Its #1 Best-Selling Rose Hips Floral Scent to Frizz Care with the New Twist & Bloom Collection
- Chief Financial Officer Schulten Andre exercised 30,677 shares at a strike of $78.52 and sold $5,184,413 worth of shares (30,677 units at $169.00) (SEC Form 4)
- CEO - Grooming Santos De Azevedo Juliana Monteiro sold $907,530 worth of shares (5,370 units at $169.00), decreasing direct ownership by 20% to 21,361 units (SEC Form 4)
- The S&P 500 Fell 2% or More on 85 Days From 2017 to 2025 and Still More Than Tripled
- SEC Form CERT filed by Procter & Gamble Company
- SEC Form 4 filed by Procter & Gamble Company
- P&G to Webcast Presentation From P&G Investor Day 2026, November 19